Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Jody LoMenzo Named Director, Investor Relations and Corporate Communications
Jody LoMenzo Named Director, Investor Relations and Corporate Communications
Tuesday October 31, 8:15 am ET
RICHMOND, Va.--(BUSINESS WIRE)--Insmed, Inc. (NASDAQ:INSM - News) announced today that Jody M. LoMenzo has joined the company to serve as Director, Investor Relations and Corporate Communications.
ADVERTISEMENT
Over the course of her professional career, Ms. LoMenzo has served in senior communications roles for Fortune companies, start-ups, and non-profits, including: the medical-surgical division of McKesson Inc. as marketing communications director; United Dominion Realty Trust, as director of investor relations and corporate communications; Infineon Technologies (White Oak Semiconductor) as communications director; and as administrative director for marketing and public relations at Bon Secours Richmond Health System.
Ms. LoMenzo also has experience on the agency side, working as director of strategic communications for the public relations division of The Martin Agency. She owned and operated her own communications strategy firm, working with healthcare clients in biotechnology and pharmaceuticals to introduce and promote new drugs. Of note, her work with Genentech for the launch of tPA, SmithKline for its Hivagen test, Amgen for Neupogen, Fujisawa for Ganite, BristolMeyer-Squibb for Cardio Tec, Sandoz for Eldyprl, and Lederle for Suprax.
Ms. LoMenzo began her professional career in television, working in New York City, as a news editor for ABC-TV's Good Morning America and as associate producer at CBS News. She received an Emmy nomination while at WABC-TV for her work as special projects producer. A graduate of New York University, she resides in Richmond.
INSM is busy executing.....
These were the wise words of one of those patient "old longs". I for one am satisfied and suggest that is happening just as described by the co. and the braintrust of respected contributors here have dicussed. We old longs have a looong term outlook so the need for daily posts to micromismanage previously stated goals and views would simply be redundant and border on pumping...a characterization I believe they are far above. I'm sure we'll see them as INSM evolves and events unfold.
GLTA
S
Shame on TRCA's pimp, Chris Raymond and Baird...
It's astounding that any analyst would be that transparent about how badly they are screwed for owning TRCA and having to put an $11 target on them in light of all the other smoke and mirrors that have been unveiled in their last two quarters worth of financials and press releases...what a crock of crap
Insmed Incorporated Reports Financial Results for the First Half and Second Quarter Ended June 30, 2006
4:03 PM EDT August 8, 2006
Insmed Incorporated (NASDAQ:INSM), a biopharmaceutical company focused on the development and commercialization of drug candidates for the treatment of metabolic diseases and endocrine disorders with unmet medical needs, today announced results for the three and six month periods ended June 30, 2006.
1st Half 1st Half $000's (except EPS) Q2 2006 Q2 2005 2006 2005 --------------------------------------------------------------------- Total Revenues 210 28 263 85 Net loss (8,911)(8,524) (22,339) (14,288) Earnings per share (0.09) (0.19) (0.25) (0.32) ---------------------------------------------------------------------
Discussion of Revenue and Expense Items
Revenues for the three months ended June 30, 2006 were $210,000 as compared with $28,000 in the corresponding period of 2005. The $210,000 revenue figure for the second quarter of 2006 was made up of $172,000 in sales to patients in our named patient program, $8,000 in sales to commercial patients and $30,000 in royalties. Commercial sales of our FDA approved drug IPLEX(TM), commenced on May 25, 2006 with the first month's supply being provided free to many of the children in order for them to begin treatment immediately rather than wait for IPLEX(TM) to be approved by the individuals' payer plan. The $28,000 of revenue for the second quarter of 2005 reflects only royalties as receipts from our named patient program for the second quarter of 2005, totalling $27,000, were classed as a reduction in expense, as we were reporting results on a research and development basis at the time.
Cost of goods sold for the second quarter of 2006 was $23,000. The cost of goods sold for the current quarter was favorably impacted by the consumption of intermediates and raw materials which were manufactured and expensed in prior quarters when all costs were classed as research and development expense.
The net loss for the second quarter ended June 30, 2006 was $8.9 million or $0.09 per share, as compared to a net loss of $8.5 million or $0.19 per share for the corresponding quarter of 2005.
The $0.4 million increase in the net loss for the second quarter of 2006 as compared to the second quarter of 2005 was due mainly to a $3.5 million increase in selling, general and administration (SG&A) expense, which was partially offset by a combination of a $1.7 million decrease in interest expense, a $1.0 million reduction in research and development expense and a $0.3 million increase in interest income.
The rise in SG&A expenses for the three months ended June 30, 2006 is mainly due to the hiring and ramping up of our commercial team and associated marketing expenses for our commercial launch of IPLEX(TM), and the recording of patent litigation expenses in the SG&A category as we commenced commercial operations in the second quarter of 2006. Prior to the second quarter of 2006 the patent litigation expenses were recorded in research and development. The decrease in interest expense is due to a $1.8 million reduction in non-cash amortization associated with the convertible debt discount on the 2005 notes, which was partially offset by a $0.1 million reduction in actual cash interest payments on the 2005 notes. The decrease in research and development expenses for the three months ended June 30, 2006, as compared to the corresponding period of 2005, was mainly due to the capitalization of inventory and construction in progress at the our production facility in Boulder, Colorado and the recording of the patent litigation expenses in SG&A. The increase in interest income for the quarter resulted from the higher level of cash on hand for investment as a result of the completion of our public offering in March of 2006.
Revenues reported for the six months ended June 30, 2006 were $263,000 as compared to $85,000 reported for the same period in 2005. The $263,000 of revenues reported for the half year were made up of $172,000 in sales to patients in our named patient program, $8,000 in sales to commercial patients reported and $83,000 from royalties. The $85,000 of revenue for the first half of 2005 reflects only royalties, as receipts from our named patient program for the first half of 2005, totalling $134,000, were classified at the time as a reduction in expense.
Cost of goods sold for the six months ended June 30, 2006 were $23,000, the same as reported for the second quarter of 2006.
The net loss for the six months ended June 30, 2006 was $22.3 million, or $0.25 per share, compared to the net loss of $14.3 million, or $0.32 per share, reported for the corresponding period in 2005.
The $8.1 million increase in the net loss for the first half of 2006 as compared to the first half of 2005 was due primarily to a $6.0 million increase in SG&A expense, a $1.9 million increase in research and development expense and a $0.9 million rise in interest expense, partially offset by a $0.6 million increase in interest income.
The rise in SG&A expenses is primarily due to the build-up of our commercial team and associated marketing expenses in connection with the launch of IPLEX(TM), together with the recording in SG&A of patent litigation expenses, which were higher than corresponding quarters. The higher research and development expenses were mainly due to higher product and process development expenses at our manufacturing facility in Boulder, Colorado, as we added personnel and continued scale up and process improvements in support of current and future IPLEX(TM) production. These increases were partially offset by the recording of patent litigation expenses in SGA and the capitalization of inventory and construction in progress. The higher interest expense results from a $1.1 million increase in non-cash amortization of the March 2005 convertible debt discount, offset by a $0.2 million reduction in actual cash interest payments, as the conversion of the March 2005 notes and warrants, which were exercised during the first quarter of 2006, resulted in an acceleration of the debt discount and a reduction in interest paid. The increase in interest income for the quarter resulted from the higher level of cash on hand for investment.
As of June 30, 2006, we had total cash and cash equivalents of $48.4 million which represents an increase of $29.6 million from December 31, 2005. This net increase is due to the $52.1 million in net cash provided by financing activities during the first half of the year, which was partially offset by the $19.5 million in net cash used during the half in support of our business operations and $3.0 million of construction in progress at our manufacturing facility. The $52.1 million of cash from financing activities was generated from a combination of $42.8 million in net proceeds from the sale of common stock in March 2006, $8.8 million from the exercise of certain outstanding warrants and $0.4 million from a reduction in a restricted letter of credit and employee option exercises.
Conference Call
We will host a conference call on Tuesday, August 8; at 4:30 p.m. Eastern Time to discuss the financial results for the first quarter of 2006 and provide a business update.
Interested investors can listen to the call over the internet from Insmed's investor relations website at www.insmed.com or by dialling (800) 361-0912 (domestic) or (913) 981-5559 (international).
A telephonic replay of the call will be available for one week at 888-203-1112 (domestic) or (719) 457-0820 (international), passcode: 1703416. A web replay of the call will be available through our corporate website, in the investor relations segment, beginning at 6:00 p.m.
About IPLEX(TM)
IPLEX(TM) is approved in the United States as the only once daily treatment for children with short stature associated with severe primary IGF-I deficiency (Primary IGFD). IPLEX(TM), a complex of recombinant human IGF-I and its binding protein IGFBP-3 (rhIGF-I/rhIGFBP-3), is the only FDA-approved IGF-I replacement therapy that also replaces deficient IGFBP-3 in these patients. The drug, which was launched in the second quarter of 2006, is also being investigated for various other indications with unmet medical needs, including severe insulin resistance, myotonic muscular dystrophy and HIV Associated Adipose Redistribution Syndrome (HARS).
For more information about IPLEX(TM) please go to www.go-IPLEX.com.
About Insmed Incorporated
Insmed is a biopharmaceutical company focused on the development and commercialization of drug candidates for the treatment of metabolic diseases and endocrine disorders with unmet medical needs. For more information, please visit www.insmed.com. Our leading product, IPLEX(TM) was approved as an orphan drug by the United States Food and Drug Administration in December 2005 for the treatment of growth failure in children with severe primary IGF-I deficiency (Primary IGFD) or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH.
Statements included within this press release, which are not historical in nature, may constitute forward-looking statements for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements regarding financial position, results of operations, cash flows, financing plans, business strategies, capital and other expenditures, competitive positions, commercial acceptance of IPLEX(TM), growth opportunities for approved or proposed products, plans and objectives of management. Such forward-looking statements are subject to numerous risks and uncertainties, including risks that we may not successfully launch IPLEX(TM), our product candidates may fail in clinical trials or may not be successfully marketed, we may lack financial resources to complete development of product candidates, we may be unable to raise additional financing necessary to continue current operations, we may not be able to sufficiently expand the manufacturing capacity of our leased manufacturing facility in Boulder, Colorado, and utilize that facility to manufacture our approved product, IPLEX(TM), and other product candidates, competing products may be more successful, we may have a negative outcome of our current litigation with third parties regarding our patent rights, demand for new pharmaceutical products may decrease and the biopharmaceutical industry may experience negative market trends. As a result of these and other risks and uncertainties, actual results may differ materially from those described in this press release. For further information with respect to factors that could cause actual results to differ from expectations, reference is made to reports filed by the Company with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended. The forward-looking statements made in this release are made only as of the date hereof and Insmed disclaims any intention or responsibility for updating predictions or financial guidance contained in this release.
SOURCE: Insmed Incorporated
Insmed Media: Kathy Jeavons, 202-835-7260; Kathy.jeavons@ketchum.com Investor Relations: Tim Ryan, 212-477-9007 x24; tryan@troutgroup.com
PLEASE NOTE: The format for the condensed consoldated #'s was unsuitable for this post...please go to www.insmed.com for the official numbers and tables.
GLTA
S
ACUS ... Anyone familiar with it? TIA
Coming off a nasty spill from $6 down to $3.50's. Just starting to graze on it some before and major dd. Here's the latest news release/propaganda.
Acusphere Completes First Commercial Scale Batch Of AI-700
7:32 AM EDT July 11, 2006
DOW JONES NEWSWIRES
Acusphere Inc. (ACUS) produced a full commercial scale development batch of AI-700, the company's lead product candidate.
AI-700 is an ultrasound contrast agent in development for the detection of coronary heart disease.
The New York biotechnology company said data from production of AI-700 under "current good manufacturing practices" is intended to be part of the new drug application submission, scheduled for the first half of 2007.
Acusphere said AI-700 is currently in Phase III clinical trials.
The company's shares closed Monday at $3.87, down 34 cents, or 8.1%.
-Josee Rose; 201-938-5400; AskNewswires@dowjones.com
(END) Dow Jones Newswires
07-11-06 0732ET
OT - ACUS ?? Anyone familiear with it? TIA
Acusphere Completes First Commercial Scale Batch Of AI-700
7:32 AM EDT July 11, 2006
DOW JONES NEWSWIRES
Acusphere Inc. (ACUS) produced a full commercial scale development batch of AI-700, the company's lead product candidate.
AI-700 is an ultrasound contrast agent in development for the detection of coronary heart disease.
The New York biotechnology company said data from production of AI-700 under "current good manufacturing practices" is intended to be part of the new drug application submission, scheduled for the first half of 2007.
Acusphere said AI-700 is currently in Phase III clinical trials.
The company's shares closed Monday at $3.87, down 34 cents, or 8.1%.
-Josee Rose; 201-938-5400; AskNewswires@dowjones.com
(END) Dow Jones Newswires
07-11-06 0732ET
Last August earnings was on the Monday the 8th...
I think it's fair to expect them this year on Monday, August 7th, though I wouldn't be surpised if they released them anytime before the 14th.
Here's an interesting link for ref :
http://www.companyboardroom.com/company.asp?ticker=INSM&client=cb&19415
glta
s
Completely Concur Readi...
That market is already a who's-who in the pharm industry with products on the mkt or have ongoing trials for the less severe growth disorders. If it helps Butch..., grazing through clinictrails.gov is worth the time to see all the players in that field.
Correct me if i'm wrong please, but the trca trial is an extention of their previous trial so would it be germain to think that their going to use the 2X/day dosing for those patients,too? hmmm
tia and glta
added today, btw
s
Presentation link
http://www.wsw.com/webcast/ceut4/insm/
OofDah!! lol
Not a TA expert but fwiw...
I am not convinced weve broken the downtrend until the 1.13 is tested again and we could very well see it played by the pro's to test a buck. Last Sept-Nov saw a nice base built and IMHO will be our ceiling until we stablize with
1. sales growth and market share reports
2. litigation success and/or
3. volume capitulation.
I would love to be convinced that 7/5 was the capitulation because I want to add more...though I'm now averaging down. First shot of good news and I beleive we'll head straight up to the 20 DMA as we have done before(around $1.43 now).
I am very greatful that I was on vacation last week so I didn't have a meltdown. Thank you to all who have posted here since with some very somber,sober and realistic insight regarding recent events.
Long and glta
S
Looking Forward to Towbin Unter's Update
in light of all that's transpired in the last 3 month's since that was written. This was put out before TRCA's last qtr earnings and disasterous conf.call, case dismissal in CA, mkt cap plunge, INSM's launch and presentations, etc.,etc.
8:45am Market Pulse Announces Its AM Stock Picks for Tuesday, June 27, 2006: GOOG, NSOL, INTC, INSM
"Insmed Inc. (Nasdaq INSM): Attractive"
OT- Bingo! Whole Heartedly Concur
It's too easy to label any group cultish after presenting oneself to any forum/group and then failing to produce sound/substanciated responses once your statements, facts or figures are challenged.
The next time it's a slow day and you want to see truly 'cultish', I mean the Rev.Jim Jones style, go visit any RMBS, SIRI, HSY, or any stem cell board for an eye opener. They are rabid! My favorite was HSY cause of the old guard vs. new guard. It's almost as much fun as watching two really old guys fistfight,(my teenage son showed me a hysterical short vid he found,( http://www.ebaumsworld.com/videos/oldguyfight.html ) It's Friday and I don't care who you are it's funny.
"to what purpose?" you asked...there's that manipulation issue again masked in the anonymous sanctity provided by the internet.
Meanwhile, orders filled for YMI this am. Thanks to those here for the great insights and subject posts.
glta
s
Y3 - I would suggest Dew's opinion regarding the insm "cult" is rooted in a recent ymb style flameout he had on that board with a poster he banned from here. Having seen you in there before I am confident you'll be able to draw your own conclusions about it's "prevailing tenor".
Dew - I've followed you and this board for quite awhile and thought you were above such dim characterizations of another successful ihub board based on your personal clashes with one poster. I'm disappointed.
Meanwhile, I have enjoyed the intelligent and substance filled info and discussions that prevail on both this and the insm boards and hope it never disinigrates to six year old in a sandbox crap that prevails nearly everywhere else.
glta
s
Who will be first to $2? is now the question...
$^)
edit (10:05am): Looks like everyone's thinking the same thing, drbio, lololol
Very interesting DNA's footprint in CA
could not garner the muscle needed for TRCA's case. Wasn't the judge a US District therefore Fed, therefore looks like WE are paying and possibly getting our money's worth, lol.
My favorite line fm the ruling/sec filing:
"Her ruling also indicated that the complaint should establish that the requisite false statements were disseminated to consumers of Increlex™, e.g., the physicians who purchase and prescribe Increlex, rather than solely to investors."
Doesn't that basically say "Y'all need to do better homework before wasting my time, let it go or go bother somebody else." ?? lol ??
Based on TRCA's last QTRLY and Annual, TRCA's legal expenses were going to consume 32-37% of cash on hand? Please correct me if I'm wrong...Now they want to keep paying the lawyers to rekindle this in VA??..nothing but desparation, imho.
S
Jelly, Cue and Dunno...Let it go... for now
Alot of very hard work, dd, and research by some very sharp minds have contributed to this board, please do not make it your sounding board for your current conversation/dissagreements...try email/phones/im's/meeting for drinks/etc. but please don't make this even begin to resemble the rest of the 3ring circus's out there....I think the posters/readers here have something special going on, lets not spoil it.
Jelly, I truly appreciate your keen observations, nice catch...not only wrt INSM but also regarding your concerns/efforts to keep this board from disinigrating the success of this board. These guys step out of line I have confidence the moderator/s will stone them.
Cue and Dunno, Welcome and please contribute and/or encourage thoughtful insite and/or discussion here.
Meanwhile, I'm still adding at these amaZing levels!!
GLTA
S
Re: trca files lawsuit against insmed.eo
by: sheepherder1976
Long-Term Sentiment: Strong Buy 06/12/06 02:58 pm
Msg: 105395 of 105395
Tercica, Inc. today filed a complaint in the U.S. District Court for the Eastern District of Virginia, Richmond division alleging Insmed Incorporated violated the Lanham Act and related statutes relating to false advertising and unfair competition. This action was taken after the presiding Judge for the U.S. District Court for the Northern District of California, the Honorable Saundra Brown Armstrong, dismissed on June 9, 2006 Tercica’s complaint for the same violations on the basis that she could not exercise jurisdiction over Insmed, which is based in Virginia. Her ruling also indicated that the complaint should establish that the requisite false statements were disseminated to consumers of Increlex™, e.g., the physicians who purchase and prescribe Increlex, rather than solely to investors. Tercica’s re-filing adds new allegations of false and misleading advertising that Insmed disseminated specifically to pediatric endocrinologists, who for purposes of the Lanham Act and related statutes are among the relevant community of consumers affected
HOW F'n desperate is that? 1st impression, trca just put a huge hole in their sail for the already outstanding legal battle.
Tercica Files Lawsuit Vs Insmed >TRCA
2:53 PM EDT June 12, 2006
?? on DJ just now. no details yet. anyone else?
YMB posters are for the most part not very helpful (IMHO)...
or very bright!!!!
If Y'all are doing it right...
coinz, recurv, io_io, chem24, rstor, drbio, jelly,mpet, beachchic, biowatch, ED, xoxo, DooDD, CT, etc., right now if you put on Deodato's "Also Sprach Zarathustra" (his jazz version of 2010 Space Odessey) sit back and relax you'll begin to feel what the ride will be like as INSM transforms from a biotech co. to a pharma!! btw coinz, nice opening pic for this page.
Enjoy!
S
Wall's other 2 or 3 <$300M cap
I don't know if INSM is one of your other 2 or 3 but I've been adding all week.
I'm particularly pleased that 1)it is holding up rather well these last 2 days in light/spite of the blood bath out there as beachgal puts it. and 2) the institutional ownership has more than doubled
"He's a lying pumping", hyping,self-serving,....
egomaniacal, smug, dillusional,.....Did anyone see his program last night where he spent the bulk of it trying emphasize humility and learning from mistakes? I almost wet myself laughing so hard. His show must be in trouble because he was no more convincing than Clinton and his " I did Not have sessual relations with that woman" speech.
sorry for the rant, they guy is the posterboy for everything that is wrong with the markets and he doesn't know it...yet.
Speculation on Coinstarz.......
First and foremost, please know the thoughtful and enourmous efforts of Coinstarz regarding the establishment of this board, it's informative content and the constructive insight it inspired by all that use it can Never be underestimated!
Thank you coinz and everyone.
Speculation on Coinz - I might suggest that your taking BS flak from someone and have become guarded enough to have to worry about CYA everytime you post. I would suggest you needn't worry because you've made your position and your intentions here known to all so that anyone with half a brain would know the level of your sincerity. My hope is that you and anyone else with useful information won't be afraid or hesitate to post thoughts, challenge ideas, provide insite and certainly Speculate.
Of course this post is my personal opinion only. lol
Not eye said the blind man...
In light of the very dramatic/drastic haircuts in the pps for several of the more recent "losers" (NBIX, THLD, ESCL, RIGL for ex.) I have a question that is nagging at me...
What determines the point at which these disasters fall to on their plunge? What criteria is being used to set these price levels?
TIA
S
I'll 3rd that...and also added more
Anyone nibbling on THLD at this level?
FDA halted trial of their prostrate drug for liver toxicity. Down 75%
tia
s
y3 - Yes, the #'s are from their 10Q
http://biz.yahoo.com/bw/060509/20060509006227.html?.v=1
I tried to copy that section here but the format got all jumbled..thats what I get when i'm not smarter than the machine I work with. 8^)
Hope that helps
s
Wall - Welcome aboard. From the 10Q -
"Selling, General and Administrative Expenses. Selling, general and administrative expenses increased to $10.5 million for the quarter ended March 31, 2006, from $4.2 million for the same period in 2005. The increase of $6.3 million was primarily attributable to additional expenditures associated with sales and marketing activities of $2.8 million, increased expenses associated with litigation of $2.2 million, and increased expenses associated with medical education of $0.5 million"
I know this doesn't fully answer your question because the 10Q doesn't set out what part of the $4.2M in the same total expenses in this catagory were for litigation. I'm left to hazard an assumption that the $6.3M in S,G,A Expenses increase this qtr were comprised of 44% in litigation expenses, we can extrapolate that to the total $10.5M, it appears they are spending in the neighborhood of $4-5M on legal fees/qtr (=$16-20M/year?) Their total expenses for the 1Q was reported at $15.2M so a ballpark figure of 30%/qtr for litigation expenses looks safe. What do you think?
Bottom line, TRCA is putting more into litigation than R&D, about as much as their sales and mktg efforts and is literally trying to save themselves with this litigation attempt. How incredibly desperate!
Unaswered Questions During the Q&A
After listening to the conf.call I came away with the same take following the QandA as this ymb post. I was especially startled by the clumsiness with which the question regarding whether patients could switch medications was handled and the abruptness by the TRCA mgmt member when he cut off the guy struggling with the answer. For those of you that listened, what is your take on this, tia
UNANSWERED Questions fm CC
by: hardknox49
Long-Term Sentiment: Strong Buy 05/09/06 05:23 pm
Msg: 93809 of 93811
Here's a list of the Questions they did NOT answer when asked...please correct my notes if needed but that was worse than their last CC and one of the worst I've ever heard. Scientists should not be given a microphone...EVER!
1. Tom Schrader/Harris Nesbit wanted to know more about the 300 Identified patients...were they new or previously ID'd.
2. Chris Raynard(sp)/Robert Baird wanted an update on phase 3b for the expected enrollment and a timeline to which they replied "Things are fine and we're not prepared for specifics" and would not provide any update until 2Q.
3. Matt Osborne/Lazard asked them address 1)Off label uses and Rx and got no reply...2)Were there any promotions or free drugs to which they made him ask what did he mean and stated they did not "give any free drugs at the start of the launch" at which point that TRCA speaker was immediately interupted by another mgmt member who went off the subject!...3)What was the # of patients on at the end of the qtr and are there any paying customers yet. They stated that no enrolled patients have rolled over to paying customers.
4. SG Cowen rep asked how many committed of the 300 ID'd patients and could they switch medications midstream during treatment. This was amazing as there was literally 5 seconds of "Ah, Uh, Ah, Duh..." before someone cut off the stammerer and said and I quote " there are no guarentees" ... whatever that meant.
GNBT PR/IR is WORSE!!!
They have zero credibility because they do GNBT an incredible disservice by putting out fluff and bs too often. The only people they're placating are the daytraders and short term traders. That's a flippers paradise. I would never put long term investment money in that stock.
Anyone who has done their DD here know the milestone events and when their going to happen. We also understand the inherent risk and the potential with investing, yes investing in this biotek(It's going to be cool when we get to call this a pharmaceutical down the road). I remember clearly that those that first drew my interest to INSM made no bones from the onset that this opportunity would work best for those with a long term horizon and patience and I thank them for that.
The pps is disappointing...for now, but i still contend the loudest bitching we're seeing is from those that are playing INSM for a quick trade. fwiw, we saw YMI languish for a long time at $2-3 while they were executing their business plans and no ones complaining now.
I'm adding and glta!
s
DYOR - Your Quiet Period Question
I'm sorry I posted and ran during y'day's storms without addressing your quiet period Q. Below are two earlier posts to this board that answer that for us both. Check out the link, too.
Posted by: ED20332
In reply to: None Date:3/28/2006 7:53:55 PM
Post #of 1283
Quite period ending 3/31/2006
http://pro.edgar-online.com/ipo/displayFundamentals.asp?cikid=72143&fnid=48478&IPO=0&con....
and
Posted by: money_magnet
In reply to: None Date:3/29/2006 1:45:01 PM
Post #of 1283
Quiet Period
The federal securities laws do not define the term "quiet period," which is also referred to as the "waiting period." However, historically, a quiet period is extended from the time a company files a registration statement with the SEC until SEC staff declared the registration statement "effective." During that period, the federal securities laws limit what information a company and related parties can release to the public.
DYOR, for all the real longs in INSM the pps "disappointment"
and the noise regarding it is all flotsom and jetsom...Go back and review every event since Dec. and you'll see a plan being executed.
The avg. pps all last fall was about $1.17. We all know the events that have transpired but how often do folks ask themselves what has really changed?
The one major thing that has changed is that along the way INSM has been bought higher by daytraders and novices chasing for the home run that are pissed the pps is "only" $1.88, only trades in daily penny increments since and want to blame everyone but themselves. imho these are all folks who lack vision, patience, experience or maturity it takes to be in biotechs or the stock market, and make the most noise..screw em.
Meanwhile, DYOR consider this. The pps nearly tripled in just over one month's time. the pps right now is at a 50% retracement from the hyper move it made to $3.35. Ask yourself, how many companies pps has made that kind of parabolic move and sustained it without a technical retracement? I will admit I didn't expect <$2 but the INSM story is till intact and I'm adding.
Anyway I have the luxury of being a true long and would encourage you to do the same and anytime you doubt, go listen to the last CC. When doing so try to listen to the level of confidence reflected in their voices, the organized delivery and the details of what is presented. There's no BS pr's blanketing the wires to placate the day traders.
I'm still excited about INSM and have the patience still to see this play out.
Sorry it took me 2 attempts to post this due to storms
glta
s
It's all flotsom and jetsom....
xoxo - omar the tentmaker had the validity of that same post seriously questioned when he posted earlier in the week. I could be wrong (my insm ignore ranks are pretty full in a neverending attempt to filter out the noise) but nobody else was able to verify, even those with same reporting service he said was used. He's established quit a rep for bashing INSM lately, mostly because as it was also pointed out, he has nobody to left pump to on the TRCA ymb.
U of Tennessee womens b-ball and was part of a great study regarding ACL and other injuries several years back. have you seen it? ties in nicely w/ others done at UNC, Duke, PSU womens soccer teams and by USOC, colorado springs... their training routines and regiments were altered dramatically and has trickled down to girls youth sports nicely...
I'm no conspiracy theorist but I smell a rat wrt INSM AP headline.
It just infuriates me when blanket statements included in god knows how many regularly submitted financial reports and designed soley to "shield" companies and their auditors are twisted as the AP has this morning.
Tough part is ignoring whether it's an attempt drive the pps down in a share grab or to weaken INSM image ahead of upcoming rollout ot Iplex and conference appearances. Things that make you go hmmmm!
anyway, sorry for the rant....i intent to add the dip.
I'm no conspiracy theorist but I smell a rat wrt INSM AP headline.
It just infuriates me when blanket statements included in god knows how many regularly submitted financial reports and designed soley to "shield" companies and their auditors are twisted as the AP has this morning.
Tough part is ignoring whether it's an attempt drive the pps down in a share grab or to weaken INSM image ahead of upcoming rollout ot Iplex and conference appearances. Things that make you go hmmmm!
anyway, sorry for the rant....i intend to add the dip.
Is this standard boilerplate verbage?
just like the statements of risk reqd on financing filings?
Insmed Announces Additional Information in Compliance with NASDAQ Rules
Wednesday March 22, 6:43 am ET
RICHMOND, Va.--(BUSINESS WIRE)--March 22, 2006--Insmed Incorporated (NASDAQ: INSM - News): Under NASDAQ Marketplace Rule 4350(b) any Company listed on the NASDAQ Market which receives a going concern opinion is required to press release this information to the public. In compliance with this market rule Insmed announces that in its 10K filed for the year ended December 31, 2005 the Company's auditor had modified their audit opinion due to a going concern uncertainty, as the Company's ability to continue as a going concern at the time was dependent upon its ability to raise capital through securities offerings, debt financing, and partnerships and use these sources of capital to fund operations.
ADVERTISEMENT
Subsequent to the filing of the 10K the Company was successful in completing a public offering on March 15, 2006 which, together with its current cash on hand, the Company believes is sufficient to cover the Company's operational needs at least through the second quarter of 2007. The Company raised net proceeds of approximately $42.8 million in the offering.